Form 4: Natera CFO Michael Brophy Sells Shares Under 10b5-1 Trading Plan

Natera's CFO, Michael Brophy, sold 1,378 shares of common stock on April 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 2, 2024, Michael Brophy, the Chief Financial Officer of Natera, Inc., sold 1,378 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on March 14, 2023.
• The shares were sold at a weighted average price of $92.619, with individual transactions ranging from $92.47 to $92.79 per share.
• Following the transaction, Brophy directly owns 70,646 shares of Natera's common stock.

Sentiment

Score: 5

Explanation: The document is neutral as it simply reports a transaction. The sale was pre-planned under a 10b5-1 plan, so it doesn't necessarily indicate a negative outlook.

Industry Context

Sales by company executives are a normal part of corporate governance. The fact that this sale was executed under a 10b5-1 trading plan suggests it was pre-planned and not based on any immediate inside information.

Comparison to Industry Standards

• Executive compensation and stock sales are common across the biotech industry.
• Comparing Brophy's holdings and sales to those of CFOs at similar-sized companies like Exact Sciences or Guardant Health would provide a better benchmark.
• Rule 10b5-1 plans are a standard tool used by executives to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates